Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of (+/-)Nicotine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 known ✓ | P17787 | 4/20 | 0.94 |
| ▸ | CHRNA4 known ✓ | P43681 | 4/20 | 0.94 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.94 |
| ▸ | CHRNA7 | P36544 | 4/20 | 0.94 |
| ▸ | CHRNB4 | P30926 | 3/20 | 0.94 |
| ▸ | CHRNA3 | P32297 | 3/20 | 0.94 |
| ▸ | CHRNA2 | Q15822 | 2/20 | 0.94 |
| ▸ | LMNA | P02545 | 1/20 | 0.94 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.94 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.94 |
| ▸ | PSIP1 | O75475 | 1/20 | 0.94 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.94 |
| ▸ | HTR3B | O95264 | 1/20 | 0.94 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.94 |
| ▸ | CHRNG | P07510 | 1/20 | 0.94 |
| ▸ | MAPT | P10636 | 1/20 | 0.94 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.94 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.94 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.94 |
| ▸ | CHRNA5 | P30532 | 1/20 | 0.94 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| (+/-)Nicotine SCHEMBL30339296 | 1.00 | ALDH1A1 (0.94) | ALDH1A1CHRNA7CHRNB2CHRNA4CHRNB4 | |
| Nicotine SCHEMBL4615064 | 0.98 | ALDH1A1 (0.97) | ALDH1A1CHRNA7CHRNB2CHRNA4CHRNB4 | |
| (+/-)Nicotine SCHEMBL29352733 | 0.98 | ALDH1A1 (0.97) | ALDH1A1CHRNA7CHRNB2CHRNA4CHRNB4 | |
| (+/-)Nicotine SCHEMBL27784105 | 0.98 | ALDH1A1 (0.97) | ALDH1A1CHRNA7CHRNB2CHRNA4CHRNB4 | |
| Nicotine SCHEMBL15561440 | 0.98 | ALDH1A1 (0.97) | ALDH1A1CHRNA7CHRNB2CHRNA4CHRNB4 | |
| (+/-)Nicotine SCHEMBL2390652 | 0.98 | ALDH1A1 (0.97) | ALDH1A1CHRNA7CHRNB2CHRNA4CHRNB4 | |
| (+/-)Nicotine SCHEMBL15561442 | 0.98 | ALDH1A1 (0.97) | ALDH1A1CHRNA7CHRNB2CHRNA4CHRNB4 | |
| (+/-)Nicotine SCHEMBL4615066 | 0.98 | ALDH1A1 (0.97) | ALDH1A1CHRNA7CHRNB2CHRNA4CHRNB4 | |
| Nicotine SCHEMBL9383177 | 0.97 | ALDH1A1 (0.94) | ALDH1A1CHRNA7CHRNB2CHRNA4CHRNB4 | |
| (+/-)Nicotine SCHEMBL9383182 | 0.97 | ALDH1A1 (0.94) | ALDH1A1CHRNA7CHRNB2CHRNA4CHRNB4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 831 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3813565-B1 | A METHOD FOR MANUFACTURING RECONSTITUTED PLANT MATERIAL | IMPERIAL TOBACCO LTD (GB) | 2026-03-25 | — | — | EP | claimed |
| US-12582153-B2 | Oral formulations of kava and nicotine | ROSS JERRY WAYNE (US) | 2026-03-24 | — | — | US | claimed |
| EP-3723516-B1 | A FLAVOURED MOIST ORAL POUCHED NICOTINE PRODUCT COMPRISING MONOGLYCERIDE | SWEDISH MATCH NORTH EUROPE AB (SE) | 2026-03-11 | — | — | EP | claimed |
| WO-2025245170-A1 | ORAL FORMULATIONS OF KAVA | ROSS JERRY WAYNE (US) | 2025-11-27 | — | — | WO | claimed |
| US-20250351863-A1 | Oral Formulations of Kava | ROSS JERRY WAYNE (US) | 2025-11-20 | — | — | US | claimed |
| US-20250351862-A1 | Oral Formulations of Kava and Nicotine | ROSS JERRY WAYNE (US) | 2025-11-20 | — | — | US | claimed |
| US-20250194659-A9 | METHOD FOR MANUFACTURING RECONSTITUTED PLANT MATERIAL | IMPERIAL TOBACCO LIMITED (GB) | 2025-06-19 | — | — | US | claimed |
| US-20250176609-A1 | ORAL POUCHED NICOTINE PRODUCT INCLUDING A FILLING MATERIAL COMPRISING NICOTINE PARTICLES | SWEDISH MATCH NORTH EUROPE AB (SE) | 2025-06-05 | — | — | US | claimed |
| US-12310395-B1 | Oral formulations of kava and nicotine | ROSS JERRY WAYNE (US) | 2025-05-27 | — | — | US | claimed |
| EP-4512484-A2 | EXCIPIENTS FOR NICOTINE-CONTAINING THERAPEUTIC COMPOSITIONS | Modoral Brands Inc. (US) | 2025-02-26 | — | — | EP | claimed |
| WO-2005009386-A2 | ORALLY DISSOLVING FILMS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-02-03 | — | — | WO | claimed |
| EP-1458252-A2 | TOBACCO AND/OR TOBACCO SUBSTITUTE COMPOSITION FOR USE AS A SNUFF IN THE ORAL CAVITY | Galenica AB (SE) | 2004-09-22 | — | — | EP | claimed |
| EP-1450768-A1 | ORAL CONTROLLED RELEASE FORMS USEFUL FOR REDUCING OR PREVENTING NICOTINE CRAVINGS | SMITHKLINE BEECHAM CORPORATION (US) | 2004-09-01 | — | — | EP | claimed |
| US-20040037879-A1 | Oral controlled release forms useful for reducing or preventing nicotine cravings | SMITHKLINE BEECHAM CORPORATION | 2004-02-26 | — | — | US | claimed |
| WO-2003053175-A2 | TOBACCO AND/OR TOBACCO SUBSTITUTE COMPOSITION FOR USE AS A SNUFF IN THE ORAL CAVITY | GALENICA AB (SE) | 2003-07-03 | — | — | WO | claimed |
| WO-2003039518-A1 | ORAL CONTROLLED RELEASE FORMS USEFUL FOR REDUCING OR PREVENTING NICOTINE CRAVINGS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-05-15 | — | — | WO | claimed |
| EP-0540623-B1 | ORAL OSMOTIC DEVICE FOR DELIVERING NICOTINE | ALZA CORP (US) | 1994-09-14 | — | — | EP | claimed |
| EP-0540623-A1 | ORAL OSMOTIC DEVICE FOR DELIVERING NICOTINE. | ALZA CORP (US) | 1993-05-12 | — | — | EP | claimed |
| US-5147654-A | Oral osmotic device for delivering nicotine | ALZA CORPORATION (US) | 1992-09-15 | — | — | US | claimed |
| WO-1992001445-A1 | ORAL OSMOTIC DEVICE FOR DELIVERING NICOTINE | ALZA CORPORATION (US) | 1992-02-06 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12582153-B2 | Oral formulations of kava and nicotine | PDK2, PDHA1, LDHA | CHRNB2 566/4885CHRNA4 373/4885ALDH1A1 1359/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.